Prospective studies are needed to elucidate the clinical impact of predominant Api m 10 sensitization - Figure 2
Authors/Creators
-
1.
Medical University of Graz
-
2.
University of Graz
Description
Venom immunotherapy (VIT) is the treatment of choice for patients with Hymenoptera venom allergy and provides long-term protection from further generalized reactions in as many as 95-99% of patients treated with vespid venom, and 75-85% of patients treated with bee venom. Beside well known risk factors like elevated tryptase levels it is believed that predominant Api m 10 sensitization is as well a risk factor for treatment failure in bee VIT. However, this assumption is based on a single publication
This small pilot study shows that other predominant sensitizations, such as Api m 2 and 5, may also play an important role in bee venom allergic patients with therapy failure and not only a predominant sensitization to Api m 10 as speculated since years.
The provided dataset contains all relevant data for Figure 2 of the publication.
Files
Publication_Allergy_2021.pdf
Files
(335.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:a9daed46f997dd2b99416a292ad7198b
|
16.9 kB | Download |
|
md5:9d5e69bb24617dac51ed2f0608ad4369
|
318.9 kB | Preview Download |
Additional details
Funding
- FWF Austrian Science Fund
- Grant-DOI: 10.55776/KLI836